



ISOGENICA IS ATTENDING BIO DIGITAL 2021

BIO
International
Convention
DIGITAL 2021

HOSTED BY
Bio
Biotechnology
Innovation
Organization

Connect With Us!

AT BIO DIGITAL 2021
JUNE 10-11 & 14-18

Accelerating a BIO-Revolution through global partnerships, collaboration, and thought leadership

A graphic of three stylized human figures in blue, purple, and pink, representing a family or a group of people.

Meet David Mead, Director of Business Development and Associate Director of Marketing, Dr Mandeep Sehmi at the **BIO International Convention Digital 2021 June 10-11 & 14-18**, to learn the latest developments of VHH single domain antibodies to tumour targets. Isogenica will be sharing how VHH can be versatile biotherapeutics with carefully designed affinities, valencies and specificities to enable refined cell targeting and modes of action.

[Contact us to arrange a meeting](#)

Press Release: Dr William Eldridge appointed CSO

Dr William (Bill) Eldridge will be leading the company into its next phase, focussing on the creation of highly developable candidate therapeutic antibodies that our partners can accelerate into the clinic.



[Read the press release](#)

VHH APPLICATIONS

Isogenica's clinically validated VHH antibodies offer great benefits when assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including [CAR-Ts](#).

In collaboration with biopharmaceutical partners over the last decade, Isogenica has developed a deep pipeline including two clinical assets (Phase I and II respectively) and numerous **partnered discovery and pre-clinical stage programs with cutting edge global biotech.**

[LEARN MORE ABOUT PARTNERED DISCOVERY](#)

[view this email in your browser](#)



Copyright © Isogenica 2021 All rights reserved.



Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).